Pharmacokinetics of propionyl-L-carnitine in humans: Evidence for saturable tubular reabsorption

British Journal of Clinical Pharmacology

Volumn 50, Issue 5, 2000, Pages 441-448

  Pace, S ^a   Longo, A ^a   Toon, S ^a   Rolan, P ^a   Evans, A M ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Acetyl L carnitine; L carnitine; Nonlinear pharmacokinetics; Propionyl L carnitine; Renal clearance; Renal metabolism; Tubular reabsorption

Indexed keywords

CARNITINE DERIVATIVE; LEVACECARNINE; PROPIONYLCARNITINE; UNCLASSIFIED DRUG;

ADULT; ARTERY DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; KIDNEY METABOLISM; KIDNEY TUBULE ABSORPTION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

ABSORPTION; ACETYLCARNITINE; ADOLESCENT; ADULT; CARDIOTONIC AGENTS; CARNITINE; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY TUBULES; MALE; MIDDLE AGED; PLACEBOS;

EID: 0033729907     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00280.x     Document Type: Article

References (22)

1. Effect of propionyl-L-carnitine on quality of life in intermittent claudication
2. Propionyl-L-carnitine in intermittent claudication: Double-blind, placebo-controlled, dose titration, multicentre study
3. Propionyl-L-carnitine
4. The pharmacology of carnitine
5. The propionyl-L-carnitine hypothesis: An alternative approach to treating heart failure
6. Control of oxidative metabolism in volume -overloaded rat hearts: Effects of propionyl-L-carnitine
7. Uptake of [N-methyl-11C]propionyl-L-carnitine (PLC) in human myocardium
8. Propionyl-L-carnitine: Labelling in the N-methyl position with carbon - 11 and pharmacokinetic studies in rats
9. Disposition of L-carnitine (LC), acetyl-L-carnitine (ALC) and propionyl-L-carnitine in the rat isolated perfused liver
10. Excretion and metabolism of propionyl-L-carnitine in the isolated perfused rat kidney
11. Disposition of L-carnitine and acetyl-L-carnitine in the isolated perfused rat kidney
12. Primary systemic carnitine deficiency. II. Renal handling of carnitine
13. Pharmacokinetics and safety of 1-carnitine infused i.v. In healthy subjects
14. Plasma and urine pharmacokinetics of free and short-chain carnitine after administration of carnitine in man
15. Pharmacokinetics of bolus intravenous and oral doses of L-carnitine in healthy subjects
16. Determination of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine in human plasma by high-performance liquid chromatography after pre-column derivatization with 1-aminoanthracene
17. Multiple-dose pharmacokinetics and bioequivalence of L-carnitine 330-mg tablet versus 1-g chewable tablet versus enteral solution in healthy male volunteers
18. Comparison of L-carnitine pharmacokinetics with and without baseline correction following administration of a single 20-mg/kg intravenous dose
19. Absorption and excretion of L-carnitine during single or multiple dosing in humans
20. Protein binding of L-carnitine family components
21. Propionyl-L-carnitine: Labellin in the N-methyl position with carbon - 11 and pharmacokinetic studies in rats
22. Uptake of [N-methyl-11C]propionyl-L-carnitine (PLC) in human myocardium